Literature DB >> 2992292

Mechanisms of vasodilation induced by vasoactive intestinal polypeptide in rabbit mesenteric artery.

T Itoh, T Sasaguri, Y Makita, Y Kanmura, H Kuriyama.   

Abstract

Vasoactive intestinal polypeptide (VIP; over 10(-13) M) inhibited the norepinephrine (NE)-induced contraction evoked from the rabbit mesenteric artery. Increased concentrations of VIP (over 10(-9) M) inhibited the contractions induced by caffeine and 39 mM [K]o. However, VIP (below 10(-7) M) had no effect on the membrane potential and resistance of muscle cells. In Ca-free solution, VIP (10(-10) M) inhibited the NE-induced contraction, but the second application of NE after removal of VIP enlarged the amplitude of contraction over that in the control. Yet when 10(-9) M VIP was applied, both the first and second contractions were consistently smaller than those observed by application of 10(-10) M VIP. In Na- and Ca-free solution, repetitive applications of NE generated contractions longer than those observed in Ca-free solution. When VIP (10(-10) M) was applied once (3 min), the contraction was inhibited only once during repetitive applications of NE. VIP (over 10(-9) M) dose dependently inhibited the NE-induced contraction and had a long-lasting inhibition after washout of the tissue. In saponin-treated skinned muscles, VIP (10(-7) M) had no effect on the Ca-induced contraction or on the Ca store sites. VIP (over 10(-8) M) was about 10 times more potent than equimolar concentrations of isoproterenol in increasing the content of adenosine 3', 5'-cyclic monophosphate (cAMP). These results indicate that VIP (10(-10) M) selectively inhibits the Ca release activated by NE, and high concentrations (over 10(-9) M) would expectedly increase the Ca extrusion from cells following increase in the levels of cAMP.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2992292     DOI: 10.1152/ajpheart.1985.249.2.H231

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Persistent splanchnic hyperemia during upright tilt in postural tachycardia syndrome.

Authors:  Julian M Stewart; Marvin S Medow; June L Glover; Leslie D Montgomery
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-02       Impact factor: 4.733

2.  Splanchnic hyperemia and hypervolemia during Valsalva maneuver in postural tachycardia syndrome.

Authors:  Julian M Stewart; Marvin S Medow; Leslie D Montgomery; June L Glover; Mark M Millonas
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-06-17       Impact factor: 4.733

3.  Vasodilatation and smooth muscle membrane potential changes in arterioles from the guinea-pig small intestine.

Authors:  N Kotecha; T O Neild
Journal:  J Physiol       Date:  1995-02-01       Impact factor: 5.182

4.  The relationship between noradrenaline-induced contraction and 45Ca efflux stimulation in rabbit mesenteric artery.

Authors:  P A Leijten; C van Breemen
Journal:  Br J Pharmacol       Date:  1986-12       Impact factor: 8.739

5.  Mechanism of vasodilation induced by alpha-human atrial natriuretic polypeptide in rabbit and guinea-pig renal arteries.

Authors:  K Fujii; T Ishimatsu; H Kuriyama
Journal:  J Physiol       Date:  1986-08       Impact factor: 5.182

6.  Novel signal transduction pathway mediating endothelium-dependent beta-adrenoceptor vasorelaxation in rat thoracic aorta.

Authors:  D W Gray; I Marshall
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

7.  Nitric oxide-related vasodilator responses to parasympathetic stimulation of the submandibular gland in the cat.

Authors:  A V Edwards; J R Garrett
Journal:  J Physiol       Date:  1993-05       Impact factor: 5.182

8.  Electrophysiological analysis of neurogenic vasodilatation in the isolated lingual artery of the rabbit.

Authors:  J E Brayden; W A Large
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

9.  Effects of vasoactive intestinal peptide (VIP) on contractile responses of smooth muscle in rat stomach.

Authors:  T Ohta; S Ito; A Ohga
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.